Report Highlights Include • The Top of the California Rankings in 2022 • Where California Companies are Investing in the Future – Pipeline and Approvals • Where California Companies are Investing in the Future – Venture Financing and M&A

1. California Pharma & Biotech
Innovation Outlook
Based on California Headquartered Companies
The Top of the California Rankings in 2022
Where California Companies are Investing in the Future – Pipeline and Approvals
Product Company Therapeutic Category Phase 2022 US
$ (min)
Bictegravir/F/TAF Gilead Sciences Systemic Anti-infectives Phase III 3,061
Axicabtagene Ciloleucel Kite Pharma Oncology & Immunomodulators Filed 1,636
AR101 Aimmune Therapeutics Respiratory Phase III 923
Betrixaban Portola Pharmaceuticals Blood Filed 662
Erenumab Amgen Central Nervous System Phase III 642
Tipifarnib Kura Oncology Oncology & Immunomodulators Phase II 622
CHS-1701 Coherus BioSciences Oncology & Immunomodulators Filed 616
GBT440 Global Blood Therapeutics Blood Phase II 550
Evenity Amgen Musculoskeletal Filed 499
Neratinib Puma Biotechnology Oncology & Immunomodulators Filed 406
Total 9,618.9
Company 2022 US
$ (min)
Genentech 23,491
Amgen 17,456
Gilead Sciences 12,985
Kite Pharma 1,636
Exelixis 1,316
BioMarin Pharmaceutical 1,072
Portola Pharmaceuticals 972
Aimmune Therapeutics 923
Neurocrine Biosciences 706
Depomed 645
Top 10 Companies
Ranked on 2022 USA Sales Forecasts*
FDA Drug Name
(FDA Active Ingredient)
FDA Sponsor Applicant 2022 US
$ (min)
Tecentriq (atezolizumab) Genentech Inc 2,623
Nuplazid (pimavanserin tartrate) Acadia Pharmaceuticals Inc 1,118
Epclusa (sofosbuvir; velpatasvir) Gilead Sciences Inc 664
FDA Approvals (NME + BLA) in 2016 Ranked by 2022 USA
Forecasts
Orphan Drug Approvals by Year
Products Granted FDA First Expedited Approval*
Top 10 Pipeline Products Ranked on 2022 USA Sales Forecasts Top 5 Therapy Areas in Pipeline
California Headquartered Companies
Product Company 2022 US
$ (min)
Enbrel Amgen 3,877
Bictegravir/F/TAF Gilead Sciences 3,061
Descovy Gilead Sciences 2,636
Perjeta Genentech 2,225
Neulasta Amgen 2,193
Genvoya Gilead Sciences 2,015
Repatha Amgen 1,836
Prolia Amgen 1,775
Avastin Genentech 1,755
Xgeva Amgen 1,704
Total 23,076
Top 10 Marketed Products
Ranked on 2022 USA Sales Forecasts
Company 2022 US
$ (min)
Amgen 2,170
Kite Pharma 1,636
BioMarin Pharmaceutical 1,125
Kura Oncology 622
Gilead Sciences 475
Ultragenyx Pharmaceutical 474
Atara Biotherapeutics 408
Portola Pharmaceuticals 310
Halozyme Therapeutics 296
MyoKardia 283
Top Ten USA Orphan Drug Sales
Ranked on 2022 USA Sales Forecasts
Source: Evaluate Pharma & Biotech, May 2017
*Excluding generic sales.
*The date at which a product was first granted expedited approval for any of its indications.
No.ofFirstExpeditedApprovals
Approval Year
25
20
15
10
5
2013
14
2017 YTD
1
2016
14
2015
21
2014
9
0
2012
5
2013
4
2014
9
2015
4
2016
3
2017
YTD
2
39%
24%
9%
13%
5%
5%
5%
Oncology
Immunomodulators
Central Nervous System
Other
Systemic Anti-infectives
Gastro-Intestinal
Musculoskeletal
Cardiovascular

2. CA Industry Report – May17
Where California Companies are Investing in the Future –
Venture Financing and MA
Acquiring
Company
Target Company Target Company
Classification
MA Deal
Date
Deal Value
US $ (min)
Pfizer Medivation Biotechnology 28/09/16 14,000
AbbVie Stemcentrx Biotechnology 01/06/16 9,800
Pfizer Anacor Pharmaceuticals Biotechnology 24/06/16 5,200
Danaher Cepheid MedTech 04/11/16 4,000
Allergan Tobira Therapeutics Biotechnology 01/11/16 1,695
Top 5 California Company Acquisitions– 2016*
Venture Financing: Investments per Year / Number of Financing Rounds per Year in California
*Deal type includes company acquisitions where the target company was based in California. Deal type excludes purchase of business units,
mergers, minority/majority stakes and options.
Evaluate would like to thank staff members Fizah Khan and Jennifer Dinkel for compiling this report.
Evaluate is a leading provider of life science
commercial intelligence.
Investment($m)
Financing Investment ($ min) and Financing Count
6,000
5,000
4,000
3,000
2,000
1,000
2014
4,140
281
2013
3,103
251
2015
4,995
231
2016
4,482
199
2017
2,017
65
0
Investment Count
2013-2017 YTD
CA Venture Financing
TOTALED
$21.8B
2016 CA MA
TOTALED
$34.7B
Evaluate Headquarters
Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801
Evaluate Americas
EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109
USA
T +1 617 573 9450
F +1 617 573 9542
Evaluate APAC
Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052
Japan
T +81 (0)80 1164 4754
www.evaluate.com